메인메뉴 바로가기 본문내용 바로가기

의약품 부작용신고 및 피해구제 상담 : 1644-6223 / 14-3330

첨단바이오 포커스

국민의 안전과 건강을 지키는 한국의약품안전관리원

홈 > 알림마당 > 뉴스레터 > 첨단바이오 포커스

인쇄
게시글 보기
제목 첨단바이오 포커스 제11호
등록자 hyj0117 등록일 2021-11-05 조회수 911


















Reference

1. 식품의약품 안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=45740

2. 한국제약바이오 협회 국내 신약 개발 파이프라인 1,477개 달해, 3년만에 157.8% 증가

Available from: https://www.kpbma.or.kr/sub/select/00000000048/00000000190/208605

3. 식품의약품 안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=45780&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1

4. 식품의약품 안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=45797&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=2

5. 한국의약품안전관리원 홈페이지 Available from:

https://www.drugsafe.or.kr/iwt/ds/ko/education/EgovEduruitDetail.do?eduInfoId=RI_00000000000000280&pageIndex=1

6. “Animal models have limitations for safety assessment of gene therapies: FDA adcomm” Regulatory Focus. Last modified Sep 2. 2021, Accessed Sep 3. 2021, Available from: https://www.raps.org/news-and-articles/news-articles/2021/9/fda-adcomm-points-to-limitations-of-animal-studies

7. “Cellular, Tissue, and Gene Therapies Advisory Committee September 2-3, 2021 Meeting Briefing Document- FDA” US FDA.. Last modified Sep 3. 2021, Accessed Sep 3. 2021, Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-september-2-3-2021-meeting-announcement

8. “FDA halts tests of BioMarin drug amid heightened focus on gene therapy safety” BIOPHARMA DIVE. Last modified Sep 7. 2021, Accessed Sep 9. 2021, Available from: https://www.biopharmadive.com/news/biomarin-pku-gene-therapy-clinical-hold/606116/

9. “Convergence: Inadequate testing of cell and gene therapies draws FDA concern” Regulatory Focus. Last modified Sep 15. 2021, Accessed Sep 16. 2021, Available from: https://www.raps.org/news-and-articles/news-articles/2021/9/raps-convergence-inadequate-testing-of-cell-and-ge

10. “Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial” US FDA. Last modified Sep 29. 2021, Accessed Sep 30. 2021, Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/studying-multiple-versions-cellular-or-gene-therapy-product-early-phase-clinical-trial

11. “Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial (Draft Guidance for Industry)” US FDA. Last modified Sep 29. 2021, Accessed Sep 30. 2021, Available from: https://www.fda.gov/media/152536/download

12. “SInterpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations” US FDA. Last modified Sep 29. 2021, Accessed Sep 30. 2021,Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interpreting-sameness-gene-therapy-products-under-orphan-drug-regulations

13. “Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations (Draft Guidance for Industry)” US FDA. Last modified Sep 29. 2021, Accessed Sep 30. 2021, Available from: https://www.fda.gov/media/152536/download

14. “Committee for Advanced Therapies (CAT): work-plan-Sep” EMA. Last modified Sep 16.

2021, Accessed Sep. 20. 2021 Available from: https://www.ema.europa.eu/en/documents/committee-report/cat-monthly-report-application-procedures-guidelines-related-documents-advanced-therapies-october_en-7.pdf

15. “What’s new” EMA. Last modified Sep 29. 2021, Accessed Sep 29. 2021 Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring

16. “Orphan designations-eu3151579” EMA. Last modified Sep 15. 2021, Accessed Sep. 17. 2021 Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3151579

17. “Orphan designations-eu3192220” EMA. Last modified Sep 15. 2021, Accessed Sep. 17. 2021

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3192220

18. “Orphan designations-eu3151552” EMA. Last modified Sep 15. 2021, Accessed Sep. 17. 2021

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3151552

19. “Orphan designations-eu3151553” EMA. Last modified Sep 15. 2021, Accessed Sep. 17. 2021

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3151553

20. “Orphan designations-eu3151572” EMA. Last modified Sep 15. 2021, Accessed Sep. 17. 2021

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3151571

21. “Orphan designations-eu3141393” EMA. Last modified Sep 15. 2021, Accessed Sep. 17. 2021

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3141393

22. “Orphan designations-eu3202344” EMA. Last modified Sep 16. 2021, Accessed Sep. 17. 2021

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202344

23. “Orphan designations-eu3181976” EMA. Last modified Sep 17. 2021, Accessed Sep. 17. 2021

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3181976

24. “Orphan designations-eu3151572” EMA. Last modified Sep 17. 2021, Accessed Sep. 17. 2021

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3151572

25. “Orphan designations-eu3202296” EMA. Last modified Sep 17. 2021, Accessed Sep. 17. 2021

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202296

26. Azacitidine Mylan” EMA. Last modified Sep 6. 2021, Accessed Sep. 19, 2021

Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan

27. PMDA 홈페이지 Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html

28. PMDA 홈페이지 Available from: https://www.mhlw.go.jp/stf/newpage_21099.html

29. Phil TaylorPhil Taylor, “다케다, 크론 세포치료제 알로피젤 일본 승인”, pharmaphorum(2021.09.27.)

Available from: https://pharmaphorum.com/news/takeda-bags-japanese-approval-for-crohns-cell-therapy-alofisel/

30. “FDA, '변곡점에 선' 유전자치료제 "상업화 돕는다"” 바이오스펙테이터. Last modified Jan 21, 2019, Accessed Oct 1, 2021. 

Available from: http://www.biospectator.com/view/news_view.php?varAtcId=6982

31. “[특별기고] 미국 FDA 신약 승인 최근 동향약업신문. Last modified Mar 26, 2019, Accessed Oct 1, 2021. 

Available from: http://m.yakup.com/?m=n&mode=view&nid=228661

32. APEC 규제조화센터. (2016). 미국 의약품 허가제도

33. 한국의약품안전관리원. (2020). 첨단바이오의약품 원료세포 품질 안전기준 마련 및 교육

34. “미국 규제기관 정보”, 의약품안전나라 홈페이지, Available from: https://nedrug.mfds.go.kr/pbp/CCBBC05/getRuleInfo

35. “Compliance Actions (Biologics)”, US FDA 홈페이지Available from: https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/compliance-actions-biologics

36. “References for the Regulatory Process for the Office of Tissues and Advanced Therapies”, US FDA 홈페이지Available from: https://www.fda.gov/vaccines-blood-biologics/other-recommendations-biologics-manufacturers/references-regulatory-process-office-tissues-and-advanced-therapies

37. “Overview Office of Tissues and Advanced Therapies and Division of Cellular and Gene Therapies Research Program”, US FDA 홈페이지Available from: https://www.fda.gov/media/140940/download

38. “Regulatory Actions Issued by CBER”, US FDA 홈페이지Available from: https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/regulatory-actions-issued-cber

39. “OTAT Learn”, US FDA 홈페이지, Available from: https://www.fda.gov/vaccines-blood-biologics/news-events-biologics/otat-learn

첨부파일
첨단바이오포커스 제11호 (21년 11월).pdf [26896923 byte]